Cost effectiveness of omalizumab for severe asthma in Colombia.
Jefferson Antonio BuendiaDiana Guerrero PatiñoAndrés Felipe Zuluaga SalazarPublished in: The Journal of asthma : official journal of the Association for the Care of Asthma (2023)
Omalizumab is not cost-effective in adults with severe asthma uncontrolled in Colombia. If the cost of Omalizumab is reduced by 83%, this treatment would be cost-effective in our country. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines and should be replicated to validate their results in other middle-income countries.